Factors influencing HLA sensitization in implantable LVAD recipients.
BACKGROUND
Patients bridged to transplantation (TX) with the implantable left ventricular assist device (LVAD) may be at increased risk for the development of panel-reactive antibodies (PRA) during support.


METHODS
To investigate that, we evaluated 60 patients who received the HeartMate LVAD at our institution, of whom 53 had PRA results available for analysis. T lymphocyte PRA levels were examined before LVAD, at the peak PRA level during LVAD support (PEAK), and just before TX. A PRA level more than 10% was considered indicative of sensitization against HLA antigens.


RESULTS
The only factor that had a significant effect on PRA levels before LVAD was patient's sex (1.3% for men versus 7.4% for women; p = 0.005). During LVAD support, peak PRA levels increased significantly and the sex-associated differences were no longer evident (33.3% men, 34.3% women; not significant). At the time of TX, PRAs decreased to 10.9% (men) and 7.0% (women) (not significant). We examined the influence of blood products received before TX on PRA levels. Patients who received less than the median number of total units (<median) had lower peak PRA values (22.3% versus 49.2%; p = 0.01) and TX PRA values (3.5% versus 22.1%; p = 0.02) than those receiving more than the median (>median). When examined by the type of blood product, only the number of platelet transfusions significantly increased the peak PRA (<median: 24% versus >median: 46.9%; p = 0.03). Patients who received blood that was leukocyte-depleted tended to have lower TX PRA levels (2.9%) compared with those who did not (13.9%, p = 0.18). Forty-two patients were successfully bridged to TX, with three early and two late deaths after TX. Whereas 39 patients received transplants without intervention, 3 were treated by plasmapheresis with a 77% reduction in their HLA antibody levels at TX as measured by flow cytometry.


CONCLUSIONS
Patients with the implantable LVAD are at significant risk for the development of anti-HLA antibodies during support. Although this sensitization is often transient, intervention using plasmapheresis may be useful for some patients.
Massad
M G
MG
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195-5066, USA.
Cook
D J
DJ
Schmitt
S K
SK
Smedira
N G
NG
McCarthy
J F
JF
Vargo
R L
RL
McCarthy
P M
PM
D000328:Adult; D001803:Blood Transfusion; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006353:Heart-Assist Devices; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012737:Sex Factors
D006680:HLA Antigens; D007518:Isoantibodies